Addressing the Unmet Needs of Patients With Moderate to Severe Psoriasis: A Visual Exploration of Disease Pathogenesis and the Clinical Potential of Targeting the TYK2 Pathway as a Novel Nonbiologic Oral Therapeutic Option
Beyond TNF Inhibitors: Latest and Emerging Evidence on Novel Cytokine-Modulating Strategies in the Treatment of Moderate to Severe Psoriasis
Targeting the Burden of Moderate to Severe Psoriasis: A Visual Exploration of the Role of IL-17 Inhibitors in Improving Patient Care and Quality of Life
Skip to content
